This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Neoplasms
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
-
University of Alabama Birmingham, Birmingham, Alabama, United States, 10016
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States, 85234
Mayo Clinic Phoenix, Phoenix, Arizona, United States, 85054
Arizona Cancer Center, Scottsdale, Arizona, United States, 85258
Local Institution - 01021, Tucson, Arizona, United States, 85724
City Of Hope, Duarte, California, United States, 91010
University Of California San Diego Moores Cancer Center, La Jolla, California, United States, 92093
Local Institution - 01206, Los Angeles, California, United States, 90048
Local Institution - 01043, Sacramento, California, United States, 95816
University of California, San Francisco- California, San Francisco, California, United States, 94143
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2036-11-30